These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30131069)

  • 1. HtrA1 expression and the prognosis of high-grade serous ovarian carcinoma: a cohort study using digital analysis.
    Gagné A; Têtu B; Orain M; Turcotte S; Plante M; Grégoire J; Renaud MC; Bairati I; Trudel D
    Diagn Pathol; 2018 Aug; 13(1):57. PubMed ID: 30131069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor α in high-grade serous ovarian carcinoma.
    Taube ET; Denkert C; Sehouli J; Unger U; Kunze CA; Budczies J; Dietel M; Braicu E; Darb-Esfahani S
    Hum Pathol; 2017 Sep; 67():30-36. PubMed ID: 28414091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
    Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
    Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
    Chan AM; Enwere E; McIntyre JB; Wilson H; Nwaroh C; Wiebe N; Ou Y; Liu S; Wiedemeyer K; Rambau PF; Grevers X; Morris DG; Neri P; Gilks CB; Visser F; Le N; Luo L; Cook LS; Köbel M
    J Pathol Clin Res; 2020 Oct; 6(4):252-262. PubMed ID: 32391646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of Nestin and CD133 in serous ovarian carcinoma.
    Onisim A; Iancu M; Vlad C; Kubelac P; Fetica B; Fulop A; Achimas-Cadariu A; Achimas-Cadariu P
    J BUON; 2016; 21(5):1168-1175. PubMed ID: 27837619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions.
    Davidson B; Holth A; Hellesylt E; Tan TZ; Huang RY; Tropé C; Nesland JM; Thiery JP
    Hum Pathol; 2015 Jan; 46(1):1-8. PubMed ID: 25455994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.
    Lim D; Murali R; Murray MP; Veras E; Park KJ; Soslow RA
    Am J Surg Pathol; 2016 Mar; 40(3):302-12. PubMed ID: 26551621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B7-H4 expression in ovarian serous carcinoma: a study of 306 cases.
    Liang L; Jiang Y; Chen JS; Niu N; Piao J; Ning J; Zu Y; Zhang J; Liu J
    Hum Pathol; 2016 Nov; 57():1-6. PubMed ID: 27349304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visual and automated assessment of matrix metalloproteinase-14 tissue expression for the evaluation of ovarian cancer prognosis.
    Trudel D; Desmeules P; Turcotte S; Plante M; Grégoire J; Renaud MC; Orain M; Bairati I; Têtu B
    Mod Pathol; 2014 Oct; 27(10):1394-404. PubMed ID: 24603589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of TIMP-2, MMP-2, and MMP-9 on high-grade serous ovarian carcinoma using digital image analysis.
    Desmeules P; Trudel D; Turcotte S; Sirois J; Plante M; Grégoire J; Renaud MC; Orain M; Têtu B; Bairati I
    Hum Pathol; 2015 May; 46(5):739-45. PubMed ID: 25771900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-grade Endometrioid Carcinoma of the Ovary: A Clinicopathologic Study of 30 Cases.
    Assem H; Rambau PF; Lee S; Ogilvie T; Sienko A; Kelemen LE; Köbel M
    Am J Surg Pathol; 2018 Apr; 42(4):534-544. PubMed ID: 29309296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors.
    Altman AD; Nelson GS; Ghatage P; McIntyre JB; Capper D; Chu P; Nation JG; Karnezis AN; Han G; Kalloger SE; Köbel M
    Mod Pathol; 2013 Sep; 26(9):1255-63. PubMed ID: 23558569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The gene copy number of c-MET has a significant impact on progression-free survival in Korean patients with ovarian carcinoma.
    Kim WY; Shim SH; Jung HY; Dong M; Kim SN; Lee SJ
    Hum Pathol; 2017 Jun; 64():98-105. PubMed ID: 28428108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian serous tumors of low malignant potential with nodal low-grade serous carcinoma.
    Djordjevic B; Malpica A
    Am J Surg Pathol; 2012 Jul; 36(7):955-63. PubMed ID: 22613998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The life and times of low-grade serous carcinoma of the ovary.
    Gershenson DM
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STING pathway expression in low-grade serous carcinoma of the ovary: an unexpected therapeutic opportunity?
    Huvila J; Cochrane DR; Ta M; Chow C; Greening K; Leung S; Karnezis AN; DiFeo A; Huntsman DG
    J Pathol Clin Res; 2021 Nov; 7(6):548-555. PubMed ID: 34138519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
    Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
    Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteases and their inhibitors as prognostic factors for high-grade serous ovarian cancer.
    Trudel D; Avarvarei LM; Orain M; Turcotte S; Plante M; Grégoire J; Kappelhoff R; Labbé DP; Bachvarov D; Têtu B; Overall CM; Bairati I
    Pathol Res Pract; 2019 Jun; 215(6):152369. PubMed ID: 30987833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic role of E-cadherin in patients with advanced serous ovarian cancer.
    Bačić B; Haller H; Mrklić I; Košta V; Čarić A; Tomić S
    Arch Gynecol Obstet; 2013 Jun; 287(6):1219-24. PubMed ID: 23269354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.
    Kang EY; Cheasley D; LePage C; Wakefield MJ; da Cunha Torres M; Rowley S; Salazar C; Xing Z; Allan P; Bowtell DDL; Mes-Masson AM; Provencher DM; Rahimi K; Kelemen LE; Fasching PA; Doherty JA; Goodman MT; Goode EL; Deen S; Pharoah PDP; Brenton JD; Sieh W; Mateoiu C; Sundfeldt K; Cook LS; Le ND; Anglesio MS; Gilks CB; Huntsman DG; Kennedy CJ; Traficante N; ; DeFazio A; Kaufmann S; Churchman M; Gourley C; Stephens AN; Meagher NS; Ramus SJ; Antill YC; Campbell I; Scott CL; Köbel M; Gorringe KL;
    Mod Pathol; 2021 Jan; 34(1):194-206. PubMed ID: 32724153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.